H

Hubei Biocause Pharmaceutical Co Ltd
SZSE:000627

Watchlist Manager
Hubei Biocause Pharmaceutical Co Ltd
SZSE:000627
Watchlist
Price: 4.01 CNY -4.3% Market Closed
Market Cap: 19.8B CNY
Have any thoughts about
Hubei Biocause Pharmaceutical Co Ltd?
Write Note

Hubei Biocause Pharmaceutical Co Ltd
Cash Paid for Dividends

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Hubei Biocause Pharmaceutical Co Ltd
Cash Paid for Dividends Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Paid for Dividends CAGR 3Y CAGR 5Y CAGR 10Y
H
Hubei Biocause Pharmaceutical Co Ltd
SZSE:000627
Cash Paid for Dividends
-ÂĄ831m
CAGR 3-Years
-53%
CAGR 5-Years
-26%
CAGR 10-Years
-39%
China Life Insurance Co Ltd
SSE:601628
Cash Paid for Dividends
-ÂĄ20.8B
CAGR 3-Years
7%
CAGR 5-Years
-22%
CAGR 10-Years
-4%
Ping An Insurance Group Co of China Ltd
SSE:601318
Cash Paid for Dividends
-ÂĄ62.1B
CAGR 3-Years
7%
CAGR 5-Years
3%
CAGR 10-Years
-15%
New China Life Insurance Company Ltd
SSE:601336
Cash Paid for Dividends
-ÂĄ3.8B
CAGR 3-Years
8%
CAGR 5-Years
N/A
CAGR 10-Years
-18%
S
Sunshine Insurance Group Co Ltd
HKEX:6963
Cash Paid for Dividends
-ÂĄ2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Hubei Biocause Pharmaceutical Co Ltd
Glance View

Market Cap
19.8B CNY
Industry
Insurance

Hubei Biocause Pharmaceutical Co., Ltd. is an investment holding company that engages in the insurance industry. The company is headquartered in Jingmen, Hubei and currently employs 2,239 full-time employees. is a China-based company principally engaged in insurance business, such as life insurance, health insurance and casualty insurance. The firm is also involved in pharmaceutical business and chemical business. The Company’s products include polypropylene and Ibuprofen. The firm distributes its products in domestic market and to overseas markets, with Central China and South China as its main markets.

Intrinsic Value
4.79 CNY
Undervaluation 16%
Intrinsic Value
Price
H

See Also

What is Hubei Biocause Pharmaceutical Co Ltd's Cash Paid for Dividends?
Cash Paid for Dividends
-831m CNY

Based on the financial report for Jun 30, 2024, Hubei Biocause Pharmaceutical Co Ltd's Cash Paid for Dividends amounts to -831m CNY.

What is Hubei Biocause Pharmaceutical Co Ltd's Cash Paid for Dividends growth rate?
Cash Paid for Dividends CAGR 10Y
-39%

Over the last year, the Cash Paid for Dividends growth was 58%. The average annual Cash Paid for Dividends growth rates for Hubei Biocause Pharmaceutical Co Ltd have been -53% over the past three years , -26% over the past five years , and -39% over the past ten years .

Back to Top